GlassScriptPhysician profile
Kenneth Pitman
NPI 1790716652
$6,963.06
in general payments reported to CMS, 2019-2025
53 companies · $772 in 2025
The $772 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $1,260 · 2021: $911 · 2022: $854 · 2023: $873 · 2024: $1,091 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.77 |
| Education | $380.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $815.28 | 2019-2025 | Prialt |
| Saluda Medical Americas, INC. | $548.33 | 2023-2025 | Evoke, Evoke Scs |
| Teva Pharmaceuticals USA, INC. | $525.62 | 2019-2021 | |
| Abbvie INC. | $475.25 | 2021-2025 | |
| Medtronic, INC. | $444.95 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Pfizer INC. | $335.27 | 2019-2025 | |
| Stimwave Technologies Incorporated | $299.35 | 2020 | |
| Amgen INC. | $279.79 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $270.48 | 2019-2025 | Xtampza |
| Saol Therapeutics INC. | $247.39 | 2020-2021 | |
| Nevro Corp. | $179.63 | 2020-2024 | Senza |
| Boston Scientific Corporation | $173.84 | 2019-2025 | General - Pain Management |
| Grt US Holding, INC. | $161.49 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $156.57 | 2021-2024 | |
| Allergan, INC. | $139.81 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Pitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.